micro-community-banner
 
  • Saved

1yr
Public neoantigens in breast cancer immunotherapy (Review)

Public neoantigens in breast cancer immunotherapy (Review)

Source : https://pubmed.ncbi.nlm.nih.gov/38904202/

Among women globally, breast cancer is the most prevalent cancer and the leading cause of cancer‑related death. Interestingly, though genetic mutations contribute to the disease, <15% of women diagnosed with...

Public neoantigens offer promising avenues for immunotherapy in breast cancer, leveraging shared mutations to potentially broaden therapeutic benefits beyond individualized approaches, marking a significant advancement in cancer treatment strategies.

  • Saved

1yr
Platinum chemotherapy for early triple-negative breast cancer

Platinum chemotherapy for early triple-negative breast cancer

Source : https://pubmed.ncbi.nlm.nih.gov/38492276/

Platinum-based chemotherapy using carboplatin in the adjuvant or neoadjuvant setting improves long-term outcomes of DFS and OS in early TNBC, with no evidence of differences by subgroup. This was at...

Platinum-based chemotherapy using carboplatin in the adjuvant or neoadjuvant setting improves long-term outcomes of DFS and OS in early TNBC.

  • Saved

1yr
Use of Antibody-Drug Conjugates in the Early Setting of Breast Cancer

Use of Antibody-Drug Conjugates in the Early Setting of Breast Cancer

Source : https://pubmed.ncbi.nlm.nih.gov/38894701/

Antibody-drug conjugates (ADCs) are anticancer agents with the capacity to selectively deliver their payloads to cancer cells. Antibody-drug conjugates consist of a monoclonal antibody backbone connected by a linker to...

Several ADCs targeting HER2, HER3, TROP2, or LIV1 are in clinical trials for early breast cancer. T-DM1, T-DXd, and SG are among the advanced-stage ADCs, while promising newcomers like ARX788 and TQB2102 show favorable results, advancing treatment options.

  • Saved

1yr
ASCO 2024: Pioneering Advances and Future Directions in Oncology

The ASCO 2024 conference was a landmark event, drawing 45,000 registrants and presenting over 5,000 abstracts on cutting-edge advances and research in Clinical Oncology. The emphasis on patient-centric approaches, blending high-tech and high-touch care, underscored the commitment to improving patient outcomes and experiences.

  • Saved

1yr
Vaccine-associated axillary lymphadenopathy with a focus on COVID-19 vaccines

Vaccine-associated axillary lymphadenopathy with a focus on COVID-19 vaccines

Source : https://pubmed.ncbi.nlm.nih.gov/38906159/

Axillary lymphadenopathy (LA) after COVID-19 vaccination is now known to be a common side effect. In these cases, malignancy cannot always be excluded on the basis of morphological imaging criteria.Narrative...

Vaccination history should be well documented and taken into account when evaluating suspicious LN. Biopsy of abnormal, persistent, or progressive LNs is recommended. Preoperative staging of breast cancer should not be delayed by follow-up. The risk of false-positive findings is accepted, and the suspicious LNs are histologically examined in...